PT-141

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that activates melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. It is derived from the melanotan II structure, with modifications that maximize sexual-arousal effects while minimizing pigmentation effects. It is administered as a 1.75 mg subcutaneous injection 45 minutes before sexual activity and is sold under the brand name Vyleesi by Palatin Technologies.

The molecule was developed by Palatin Technologies starting in the late 1990s. The original parent compound, melanotan II, was a non-selective melanocortin agonist used in tanning research. Investigators noticed that subjects in melanotan II studies reported strong sexual arousal effects as a side reaction. Palatin isolated the structural features responsible and refined them into bremelanotide, which retains the MC4R activity that drives sexual response while reducing the MC1R activity that drives skin pigmentation.

Vyleesi received FDA approval on June 21, 2019 under NDA 210557. The approval was for premenopausal women aged 18 or older with acquired, generalized HSDD, the same population studied in the RECONNECT Phase 3 trials. AMAG Pharmaceuticals held the initial US marketing rights. Palatin Technologies has since taken back commercial control.

The Phase 3 Evidence (RECONNECT)

The FDA approval rested on two identical Phase 3 trials, RECONNECT-1 and RECONNECT-2 (Kingsberg et al., Obstetrics & Gynecology, 2019). The trials enrolled approximately 1,200 premenopausal women with acquired, generalized HSDD diagnosed by DSM-IV criteria. Participants were randomized 1:1 to bremelanotide 1.75 mg or placebo, self-administered subcutaneously on demand approximately 45 minutes before anticipated sexual activity, for 24 weeks.

Both trials met both co-primary endpoints. Sexual desire scores (measured on the Female Sexual Function Index, FSFI desire domain) improved meaningfully with bremelanotide versus placebo. Distress related to low sexual desire (measured on the Female Sexual Distress Scale-Desire/Arousal/Orgasm modified scale, FSDS-DAO Item 13) decreased meaningfully. Effect sizes for the desire endpoint ranged from 0.49 to 0.61, which is clinically meaningful for a chronic sexual-function intervention.

About 58 percent of bremelanotide-treated participants reported perceiving benefit, versus 35 percent on placebo. The number of "satisfying sexual events" did not reach statistical significance between groups, which is the most commonly cited limitation of the trial. What improved was desire and the quality of encounters that did occur, not necessarily the total event count.

The 52-week open-label extension (Simon et al., 2019) reported continued tolerability and sustained efficacy for women who remained on treatment. Discontinuation rates due to adverse events were moderate, dominated by nausea during early dosing.

PT-141 acts on the central melanocortin system, a circuit in the hypothalamus that integrates signals related to sexual behavior, food intake, and autonomic function. The melanocortin receptors that matter for sexual response are MC3R and MC4R, both expressed in hypothalamic nuclei involved in appetitive sexual behavior.

The mechanism is fundamentally different from phosphodiesterase type 5 (PDE5) inhibitors like sildenafil, vardenafil, or tadalafil. PDE5 inhibitors work on peripheral vascular smooth muscle. They improve the mechanical response of penile or genital tissue to sexual stimulation. They do not increase sexual desire or central arousal. PT-141 does the opposite: it acts centrally on circuits that produce arousal and desire, with downstream effects on peripheral physiology mediated through autonomic outflow.

This distinction matters clinically. Patients with HSDD have reduced central sexual drive. PDE5 inhibitors do not address the central component. Patients with erectile dysfunction often have peripheral vascular contributions. PT-141 addresses the central component but does not directly improve peripheral vasodilation. In male off-label studies, PT-141 has been most useful in patients who do not respond to PDE5 inhibitors, suggesting the central drive may be the limiting factor in those cases.

The downstream cascade from MC4R activation involves dopamine release in mesolimbic circuits that mediate motivation and reward. This is partially shared with how the brain responds to other appetitive stimuli, and it is why PT-141 has been investigated for broader sexual-function indications beyond the approved HSDD label.

Female HSDD Outcomes (RECONNECT)

The Phase 3 RECONNECT program established the female HSDD evidence base. Both trials (n approximately 1,200 combined) met both co-primary endpoints over 24 weeks of on-demand dosing.

Sexual desire (FSFI desire domain). Effect sizes ranged from 0.49 to 0.61 versus placebo, which is clinically meaningful for a chronic sexual-function intervention. The effect was apparent within the first few doses and maintained throughout the 24-week treatment period.

Sexual distress (FSDS-DAO Item 13). Distress related to low desire decreased meaningfully in the bremelanotide arm.

Perceived benefit. Approximately 58 percent of bremelanotide-treated participants reported perceiving benefit, versus 35 percent on placebo, a difference of approximately 23 percentage points.

Satisfying sexual events. Did not reach statistical significance between groups. This is the most commonly cited limitation of the trial. The drug improved desire and the subjective quality of encounters that occurred, not necessarily the total event count.

The 52-week open-label extension confirmed sustained efficacy and tolerability for women who continued treatment.

Male Off-Label Use

PT-141 is not FDA-approved for men. Phase 2 work in men with erectile dysfunction has produced the most relevant off-label evidence.

Diamond et al., 2006 studied 271 men with erectile dysfunction who had not responded adequately to sildenafil. Bremelanotide was administered intranasally at the time of testing. The response rate was approximately 34 percent on bremelanotide versus 9 percent on placebo. The trial established proof-of-concept for the central mechanism in male ED that had not responded to peripheral pharmacotherapy.

Subsequent male development was complicated by the intranasal-route blood-pressure elevation that ended the inhalation program. The subcutaneous route used in Vyleesi has been tested in men in smaller studies with subjective response patterns broadly consistent with the Diamond 2006 findings. No Phase 3 trial in male ED has been completed.

Onset, Duration, and Subjective Patterns

Across approved and off-label use, the timing pattern is consistent.

Onset: 45 minutes is the minimum recommended pre-activity dosing window. Most users report perceptible effects within 30 to 60 minutes.

Peak: 1 to 2 hours after subcutaneous injection.

Duration: 6 to 8 hours of meaningful effect. Plasma half-life is approximately 2.7 hours, but the central nervous system effect outlasts plasma exposure because of distribution and downstream dopamine signaling.

The subjective effect pattern is described by users as increased sexual interest and arousal in response to relevant stimuli, rather than spontaneous arousal in their absence. The drug increases responsiveness to sexual cues rather than producing arousal without context.

Cardiovascular Effects

PT-141 produces a small, predictable rise in systolic blood pressure of approximately 6 mmHg and a slight decrease in heart rate. The peak cardiovascular effect occurs 30 to 90 minutes after dosing. The effects are well-tolerated in patients with normal blood pressure but contraindicate use in patients with uncontrolled hypertension or established cardiovascular disease. The pre-approval intranasal program was discontinued specifically because of larger blood-pressure increases observed with that route.

Pigmentation

Bremelanotide is structurally derived from melanotan II but engineered to minimize MC1R activity, which is the receptor that drives skin pigmentation. Pigmentation effects with bremelanotide are uncommon and far less pronounced than with melanotan II at comparable doses. The structural redesign was a deliberate choice during Palatin's development program to separate the sexual-arousal effect (mediated by MC4R) from the tanning effect (mediated by MC1R).

Approved Vyleesi Label Dose

The FDA-approved Vyleesi dose is 1.75 mg subcutaneously, administered at least 45 minutes before anticipated sexual activity. The label specifies the injection should be in the abdomen or thigh, with a single-use autoinjector device that delivers a fixed dose.

The dosing limits on the Vyleesi label are:

Maximum one dose in any 24-hour period.

Maximum 8 doses per month.

These limits come directly from the RECONNECT Phase 3 trial protocols. They were not derived from formal dose-finding studies establishing toxicity thresholds, but they reflect the dosing pattern tested in registration trials.

Pharmacokinetics

Bremelanotide has a plasma half-life of approximately 2.7 hours after subcutaneous injection. Peak plasma concentration occurs within 1 hour. The drug is metabolized through proteolytic cleavage and renal excretion of metabolites. No clinically significant pharmacokinetic interactions with common medications have been documented in the bremelanotide label.

Effects on sexual response outlast the plasma half-life because of central nervous system distribution and the time course of downstream dopamine signaling in mesolimbic circuits. Subjective effects on arousal can persist 6 to 8 hours after dosing, considerably longer than plasma exposure would suggest.

Off-Label Male Compounded Protocols

PT-141 is not FDA-approved for men. Compounded preparations for off-label male use typically follow the female Vyleesi dose of 1.75 mg subcutaneously before anticipated sexual activity, with the same 45-minute pre-activity dosing window. Some clinical protocols use lower doses (0.5 to 1.5 mg) initially for tolerability assessment, particularly in patients with cardiovascular risk factors.

The clinical evidence base for the 1.75 mg dose in men is limited. The Diamond 2006 Phase 2 trial used intranasal dosing rather than subcutaneous. Direct subcutaneous male trial data is limited to smaller open-label and crossover studies. The 1.75 mg dose for male off-label use is grounded in mechanistic analogy to female HSDD rather than in formal male dose-finding work.

Discontinued Intranasal Route

Palatin developed an intranasal formulation of bremelanotide during the original Phase 2 program. The intranasal route produced effective sexual-arousal response but was associated with larger blood-pressure increases than the subcutaneous route. Some intranasal Phase 2 subjects experienced clinically significant blood-pressure elevation, including a few hypertensive events. The intranasal program was discontinued. The FDA approval was specifically for the subcutaneous autoinjector format.

Compounded intranasal bremelanotide preparations have circulated through grey-market channels since. These have no published pharmacokinetic data validating the route in current form, the manufacturing controls are not pharmaceutical-grade, and the blood-pressure profile that ended Palatin's intranasal program applies to any intranasal formulation. The peptscope editorial position is that intranasal bremelanotide should not be considered equivalent to the approved subcutaneous product.

Compounded Sublingual Troches and Other Off-Label Routes

Sublingual troches containing bremelanotide have appeared in some compounding pharmacy catalogs. The route has no published bioavailability data for bremelanotide specifically. Sublingual absorption of peptides is generally unreliable due to enzymatic degradation in oral tissues. The label-equivalent dosing for sublingual administration has not been established and any clinical effect cannot be reliably predicted from the approved subcutaneous dose.

PT-141 (bremelanotide, Vyleesi) is FDA-approved for premenopausal women with acquired, generalized HSDD. The approval is limited to subcutaneous injection. Intranasal bremelanotide was in earlier development but was discontinued after blood pressure increase in nasal-route trials. Compounded intranasal formulations and sublingual troches have no published pharmacokinetic data for those routes and are not FDA-approved.

The most common adverse event is nausea in approximately 40 percent of patients after the first dose. The rate diminishes with continued use. About 13 percent of patients in the Phase 3 trials discontinued due to nausea.

Other adverse events include flushing, injection-site reactions, headache, vomiting, and the predictable cardiovascular effects (small systolic blood-pressure rise, slight heart-rate decrease) described above. Hyperpigmentation of the face, gums, or breasts has been reported at a low rate, more common with frequent dosing.

Bremelanotide is not on the FDA Category 2 bulks list because it has a current FDA approval. Compounding pharmacies can prepare it for individual patients with prescriptions. The compound is not on the WADA Prohibited List and is not relevant to sport doping.

PT-141 occupies a unique mechanistic position. It is the only FDA-approved central-acting sexual-arousal drug.

Flibanserin (Addyi) is the other approved drug for premenopausal HSDD. It is taken daily as an oral tablet, with effects that build over weeks rather than producing acute on-demand response. Flibanserin carries a boxed warning for alcohol interaction and is more frequently associated with hypotension and sedation. The two drugs target overlapping but distinct receptor systems (serotonin/dopamine for flibanserin, melanocortin for bremelanotide).

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) address peripheral vasodilation in male erectile dysfunction. They are not approved for women and do not directly increase desire or central arousal in men. PT-141 is mechanistically complementary rather than competing.

For male off-label use in patients who do not respond to PDE5 inhibitors, PT-141 has the strongest non-PDE5 evidence base, though it remains off-label and not FDA-approved for any male indication.

Other peptides studied in sexual function include kisspeptin-10 and kisspeptin-54, which act on the hypothalamic-pituitary-gonadal axis upstream of testosterone and estradiol synthesis. The kisspeptin mechanism is different from the bremelanotide mechanism and the kisspeptins are still investigational. Oxytocin has been studied for relational and partnered sexual response but is not approved for sexual dysfunction.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.